DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced that the results of a new study have been published in the “Journal of Diabetes Science and Technology.” Titled “
Digital Therapeutics for Type 2 Diabetes: Incorporating Coaching Support and Validating Digital Monitoring,” the article reports that people living with type 2 diabetes have complicated self-care requirements that can make better health difficult to achieve. The study followed individuals who were using Dario’s digital therapeutics for diabetes management. The study participants were monitored for both clinical and self-reported impact, and tracked blood glucose levels in the Dario app over a period of three months. Study participants also worked with a live certified diabetes care and education specialist (“CDCES”). Study results noted clinically significant improvements on lab test results, platform-based data and self-reported data for individuals participating in the study, confirming the relationship between personalization and outcomes. “These findings add valuable data to the little understood application of digital self-monitoring and coaching in diabetes management,” said Dario scientific and clinical director Yifat Hershcovitz, PhD, in the press release. “Our findings provide clinical validation for digital self-monitoring to deliver personalized care alongside access to a live coach. The study demonstrates our data-driven technology is working for people with type 2 diabetes, guiding them in making effective decisions in diabetes management.”
To view the full press release, visit
https://ibn.fm/7OV73
About DarioHealth Corp.
DarioHealth Corp. is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. Dario’s next-generation, AI-powered, digital therapeutic solutions support more than just an individual’s disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions, intuitive, clinically proven digital tools, high-quality software and coaching to help individuals improve health and sustain meaningful outcomes. Dario offers one of the highest-rated diabetes and hypertension solutions on the market. The company’s cross-functional team operates at the intersection of life sciences, behavioral science, and software technology and is rapidly expanding into new chronic conditions and geographic markets, using a performance-based approach to improve its users’ health. Dario makes the right thing to do the easy thing to do. For more information about the company, please visit
www.DarioHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at
http://ibn.fm/DRIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.